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Miranda W Langendam1*, Elie A Akl2, Philipp Dahm3,4, Paul Glasziou5, Gordon Guyatt6 and Holger J Schünemann6Abstract
Cochrane Reviews are intended to help providers, practitioners and patients make informed decisions about health
care. The goal of the Cochrane Applicability and Recommendation Methods Group (ARMG) is to develop
approaches, strategies and guidance that facilitate the uptake of information from Cochrane Reviews and their use
by a wide audience with specific focus on developers of recommendations and on healthcare decision makers. This
paper is part of a series highlighting developments in systematic review methodology in the 20 years since the
establishment of The Cochrane Collaboration, and its aim is to present current work and highlight future
developments in assessing and presenting summaries of evidence, with special focus on Summary of Findings (SoF)
tables and Plain Language Summaries.
A SoF table provides a concise and transparent summary of the key findings of a review in a tabular format. Several
studies have shown that SoF tables improve accessibility and understanding of Cochrane Reviews.
The ARMG and GRADE Working Group are working on further development of the SoF tables, for example by
evaluating the degree of acceptable flexibility beyond standard presentation of SoF tables, developing SoF tables
for diagnostic test accuracy reviews and interactive SoF tables (iSoF).
The plain language summary (PLS) is the other main building block for dissemination of review results to end-users.
The PLS aims to summarize the results of a review in such a way that health care consumers can readily
understand them. Current efforts include the development of a standardized language to describe statistical results,
based on effect size and quality of supporting evidence.
Producing high quality PLS and SoF tables and making them compatible and linked would make it easier to
produce dissemination products targeting different audiences (for example, providers, health policy makers,
guideline developers).
Current issues of debate include optimal presentation formats of SoF tables, the training required to produce SoF
tables, and the extent to which the authors of Cochrane Reviews should provide explicit guidance to target
audiences of patients, clinicians and policy-makers.Background
Cochrane Reviews are intended to help providers, practi-
tioners and patients make informed decisions about
health care. After collecting, appraising and analyzing
the evidence, assessment and presentation of summaries
of the evidence support the process of going from evi-
dence to recommendations. The Applicability and Rec-
ommendation Methods Group (ARMG) has been largely
responsible for developing the methodology for this part
of Cochrane Reviews, which deal with interpretation of* Correspondence: m.w.langendam@amc.uva.nl
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Amsterdam, Amsterdam, The Netherlands
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distribution, and reproduction in any mediumthe results of the reviews and facilitating the uptake of
the information they contain. In this paper we will
present the different summary presentations, and discuss
their rationale, current format, added value and future
development. We will focus on Summary of Findings
(SoF) tables and plain language summaries (PLS) as they
are the main building blocks for dissemination of review
results to end-users. We start by outlining the work of
the ARMG and the link with GRADE Working Group.
The applicability and recommendation methods group
History
Following an exploratory meeting in 1995 at the Co-
chrane Colloquium in Oslo, the ARMG was establishedntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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groups of patients and how to best present the results of
Cochrane Reviews so that they would be readily un-
derstood and widely used. Key issues included con-
siderations on how to best present a summary of the
magnitude of effect for beneficial and harmful effects,
transparently identifying predictable causes of hetero-
geneity in the absolute effects, the influence of individual
risk or severity of illness on net effect, and patient’s
values and circumstances [1].
The new group, convened by Paul Glasziou and
Gordon Guyatt, initially focused on the review and de-
velopment of methods for addressing these issues, partly
supported by a review of past work commissioned by
the Australian National Health and Medical Research
Council [2]. The group had some input to a section of
the Cochrane Handbook, and developed a five-step pro-
cess that began with a summary of the main benefits
and harms.
As The Cochrane Library became more complete and
mature, the issues of applicability and recommendations
became more important to users of reviews. At the same
time, the awareness arose that users need optimal suc-
cinct structured and reasonably uniform summaries to
understand the key findings of the often comprehensive
Cochrane Reviews and to facilitate judgments on applic-
ability. Therefore, in 2004, at the Cochrane Colloquium
in Ottawa, Paul Glasziou and Andy Oxman led empirical
work at an ARMG workshop exploring contents of a
SoF table which would summarize the main beneficial
and harmful effects in a tabular format. This idea and a
draft SoF table was warmly received.
Encouraged by the work of the ARMG while at the
Ottawa workshop, and after being offered co-leadership
of the group, Holger Schünemann replaced Paul Glasziou
as co-convenor of the ARMG. As there was much overlap
among the work of the GRADE working group, more
intense work on common aims resulted. For example,
Holger Schünemann and Andy Oxman had led the
GRADE Working Group in producing the GRADE pro-
filer software (GRADEpro) to produce the SoF tables and
integrate with RevMan. Through work under the umbrella
of the ARMG and the GRADE working group, the SoF
table has been further developed. Since then, there has
been a slow but steady uptake of the SoF tables, which
have improved the usability of reviews, and implemented
a substantial part of the original agenda of the ARMG.
Current aim
In 2013, the mission of the ARMG was refined, becom-
ing “to develop approaches, strategies, and guidance that
support the dissemination of Cochrane Reviews and
their use by a wide range of audience with specific focus
on developers of recommendations (including guidance,guidelines, policies) and on healthcare decision makers
(e.g. clinicians, policy makers)”.
Specifically, the ARMG provides guidance to optimize
the usefulness of Cochrane Reviews by articulating rea-
sons for grading the quality of the evidence and factors
to consider when moving from evidence to recommen-
dations. The group also provides detailed guidance to
authors of Cochrane Reviews on how to apply the
factors, and to users of Cochrane Reviews on how to in-
terpret the judgments made by review authors. This in-
cludes guidance on providing the systematic review
audience with the information necessary to make judg-
ments about applicability and on making direct state-
ments about applicability. For example, the Cochrane
Handbook for Systematic Reviews of Interventions ex-
plains what the review author can do to help the user to
apply the study findings to the population at large or a
specific person: “Cochrane review authors must be ex-
tremely clear on the population, intervention, and out-
comes that they are intending to address. A crucial step
is the specification of all patient-important outcomes
relevant to the intervention strategies under compari-
son” [3].
The ARMG also takes responsibility for training the
editorial teams of Cochrane Review Groups and review
authors to enable the development of SoF tables. Mem-
bers of the ARMG conduct research on the applicability
and the presentation of evidence. In addition, the group
disseminates relevant research conducted by its mem-
bers and other investigators.
Membership, scope of work and objectives of the
ARMG overlap with those of the GRADE Working
Group (in fact, at the Melbourne Colloquium in 2005,
the GRADE Working Group considered whether or not
they should merge with the ARMG and operate un-
der the Cochrane umbrella only). The GRADE Working
Group began in the year 2000 as an informal collabor-
ation of people with an interest in addressing the short-
comings of grading systems in health care. The working
group has developed a common, sensible and transpar-
ent approach to grading quality of evidence and strength
of recommendations and is working to improve this ap-
proach. Many international organizations have provided
input into the development of the approach and have
started using it (www.gradeworkinggroup.org). Through
numerous workshops and training events the GRADE
working group has both disseminated the SoF tables and
enhanced the profile of the ARMG.
Summary presentation of evidence in Cochrane
Reviews
The Cochrane Collaboration launched several initiatives
in recent years to develop and evaluate summaries of
Cochrane Reviews for different target groups [4]. The
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[4,5], while different formats of the PLS have been deve-
loped mainly for consumers [6,7].
There has been a realization over the last few years that
health professionals may not be at much more ease than
consumers in understanding and interpreting statistical
information, even when presented in a SoF table. At the
same time, some consumers might be interested in more
detailed information than that presented in a PLS.
Summary of findings tables
SoF tables are becoming an integral part of Cochrane
Reviews by providing a concise and transparent sum-
mary of the key findings of a review. At present, SoF
tables are more frequently used in Cochrane Reviews
than in other systematic reviews and studies have dem-
onstrated that they improve the accessibility and under-
standing of Cochrane Reviews [4,5]. However, they have
been featured in prominent journals, such as The New
England Journal of Medicine [8].
SoF tables aim to provide a succinct, easily interpre-
table presentation of the evidence for healthcare pro-
viders to make well-informed decisions [9,10]. Critical
elements include the confidence in the effect estimates
(quality of evidence) and magnitude of effects. The sys-
tem of assessing the quality of the evidence was devel-
oped by the GRADE Working Group [11] and adopted
by the Cochrane Collaboration.
Format
The current format of the SoF table is the product of
several initiatives of the ARMG and the GRADE Working
Group to develop and evaluate summaries of Cochrane
Reviews for different target groups [12]. Examples of the
current format of a SoF table are presented in Figure 1.
The types of information that could be included in a SoF
table are as follows:
1) A list of all important outcomes; both desirable and
undesirable.
2) A measure of the typical burden of these
outcomes (for example, control group risk,
estimated risk).
3) A measure of the risk in the intervention group,
(or alternatively, or in addition, a measure of the
difference between the risks with and without the
intervention).
4) The relative magnitude of effect.
5) The numbers of participants and studies addressing
these outcomes.
6) A rating of the overall confidence in effect estimates
for each outcome (which may vary by outcome).
7) And possibly, a comments section that provides
clarification and/or additional information.Supported by the Cochrane Methods Innovation Fund
(MIF), the groups are currently working on alternative
formats for the SoF tables.
The SoF table differs from GRADE evidence profiles
(EP) in the presentation of the quality assessment of
each factor that determines the quality of evidence for
each outcome (for example, the reason for downgrading
due to study limitations). In GRADE EP this is presented
in detail, while in the SoF table the quality of the evi-
dence assessment is only provided in key information
needed for decision-making. They represent a comprom-
ise between simplicity (to make information as easily
understandable to a wide audience) and completeness
(to make the information and the underlying judgments
as transparent as possible, but avoiding unnecessary
detail).
Outcomes
SoF tables present the outcomes that have been judged
to be critical for decision-making. Each of these out-
comes should be patient-important rather than a surro-
gate outcome and their number should be limited to
seven, a result of the work done at the workshop at the
Cochrane Colloquium in Ottawa in 2004. The choice of
seven outcomes, however, is also based on work in the
field of psychology, indicating that humans find it diffi-
cult differentiating beyond seven factors, and serves the
purpose of keeping the presented information manage-
able [12]. This requires authors of Cochrane Reviews to
prioritize outcomes based on their perceived importance
(ideally, at a very early stage of the work on their review)
as well as potentially aggregating related, yet different,
outcomes of approximately equal importance in one out-
come measure (for example, combined outcome of
gastrointestinal side-effects for patient risk for experien-
cing either vomiting and/or diarrhea).
Although the SoF table should focus on the patient-
important outcomes, there are situations in which there
may not be direct evidence for these outcomes. In that
case, reviewers should present their inferences regarding
treatment effect from the surrogate outcomes measure;
and this should be clearly labeled. The authors would do
this by using the best estimate of the baseline risk for
the patient-important outcome (see below) and then ap-
plying the relative effect from the surrogate outcome.
Another special situation may arise when the quality
of evidence is low or very low for the relevant, patient-
important outcome and a related, indirect outcome mea-
sure exists that is (rightly or wrongly) perceived to be
highly relevant by the clinical community. In such situa-
tions, indirect evidence may be presented, but authors
should be explicit about its role as a surrogate measure.
In general, SoF tables should present the highest qua-
lity of evidence available for a given outcome. When the
Figure 1 Snapshot of a Summary of Findings (SoF) table.
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randomized trials and observational studies), SoF tables
may include summaries of both. It is also possible that
review authors found no published evidence regarding
one or more critical or important outcomes.
Baseline risk
An important issue for decision-making is the deter-
mination of a baseline risk for a particular patient-
important outcome. GRADE recognizes that thepatients in randomized trials may be unrepresentative
of the general population (for example, they may
have been selected for being at high risk, thereby re-
ducing sample size requirements) and that this base-
line risk varies for prognostic subgroups. Therefore,
calculating absolute measures of effect size directly
from the data from randomized trials may be mis-
leading. Instead, baseline or control group risk
should be drawn from well-designed observational
studies if available [12].
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GRADE suggests using the median risk (rather than the
weighted average, which is influenced by outliers) among
the control groups in the included studies. If there is im-
portant variation on control group risk, GRADEPro soft-
ware (computer program developed by Jan Brozek, Andy
Oxman and Holger Schunemann) (provides the oppor-
tunity for authors to present a range of risks upon which
the calculation of absolute effect size measures is then
based. To date, GRADE has shied away from also seeking
to quantify the uncertainty surrounding the estimates of
baseline risk [12]. This has been a pragmatic decision to
avoid additional complexity, which may make the syste-
matic review process unmanageable.
Effect size presentation
Based on studies of consumer numeracy, effect size pre-
sentation as natural frequencies, that is, as event per 100
patients, for example, is preferred over presentation of
relative risks [13]. Recent data (from ongoing research),
however, suggest percentages may do as well and some-
times better. User testing of evidence profiles of guide-
line panelists randomized to four different presentation
features has further documented the value of presenting
absolute risk differences [14]. Whether or not to include
them was an issue of intense debate at the GRADE
working group meeting, held in conjunction with the
Cochrane Colloquium in Sao Paolo (2007). Absolute
measures of effect should be presented in conjunction
with confidence intervals reflecting the underlying preci-
sion and indicate the length of follow-up to which esti-
mates refer.
Whereas relative and absolute effect sizes used to
report the results of dichotomous measures are very
familiar to clinical audiences, summary measures for
continuous outcomes present particular challenges to in-
terpretation [15]. The most common approach divides
the difference in means in each study by its standard de-
viation and presents pooled results in standard deviation
units (standardized mean difference). Its drawbacks in-
clude the vulnerability to heterogeneity and difficulties
in interpretation.
One approach advocated in the interest of improved
interpretability is the reporting in minimal important
difference (MID) units, when the MID is known. Ano-
ther related approach is to use the MID as the threshold
value for converting a continuous outcome into a binary
outcome and then presenting relative and absolute effect
sizes [15].
Uptake of SoF tables
Since 2008, the uptake of SoF tables in Cochrane Re-
views has increased steadily. In Issue 1, 2009 (quarterly
issue) of The Cochrane Library, 3 reviews included a SoFtable, and this number had increased to 94 reviews in
the Issue 1 to 3, 2012 (monthly issues). In March 2012, a
total of 502 Cochrane Reviews included one or more
SoF tables. The quality of this set of SoF tables is cur-
rently being evaluated by the ARMG. As of September
2013, almost one thousand reviews include a SoF table.
According to the Methodological Standards for the
conduct of new Cochrane Intervention Reviews, inclu-
ding a SoF table is highly desirable and assessing the
quality of the body of evidence is mandatory for new
Cochrane Intervention Reviews.
Added value of SoF tables
The added value of SoF tables was first evaluated in
2005, in an unpublished pilot study headed by Gunn
Vist in collaboration with Andy Oxman, Paul Glasziou,
Julian Higgins and Holger Schünemann. Twenty
authors from 17 Cochrane Review Groups (CRGs)
were asked to construct a SoF table for their new or
updated review. The authors spent on average an
additional 4 hours (range 2 to 40 hours) on their re-
view in order to do this. In general, the authors
reported that the layout of the SoF Table was clear,
and that presenting the review results in a SoF table
was found to be helpful. Of the 17 CRGs, 11 con-
cluded that the accessibility of the review was in-
creased, 5 CRGs concluded that the quality of the
review was improved and 1 CRG rephrased the con-
clusions. Most CRGs experienced software difficulties.
The added value of SoF tables was also tested in users
of Cochrane Reviews. Two small randomised trials
found that including a SoF table in a systematic review
improved the user understanding and rapid retrieval of
key information [5]. However, the uptake of SoF by re-
view authors has not been optimal. There may be several
reasons for this. The standard table does not provide re-
view authors with enough flexibility to accommodate for
different kinds of reviews. Some people also perceive the
tables to be compact and full of data making them too
complex for the users (see Figure 1).
During development, user testing of these tables had
revealed one of the main challenges as a “tension bet-
ween achieving precision and simplicity” [5], where pre-
cision refers to comprehensiveness. Comprehensiveness,
however, to an untrained eye, can quickly become visual
clutter that camouflages the main messages.
The SoF development team addressed this tension by
using a layered approach, allowing some parts of the
table to emerge as more important to the eye than other
parts, through typographical and color differentiation.
However, this typographical layered approach was largely
not implemented due to the difficulty of technical imple-
mentation in website and PDF formats, compromising
the balance of precision and simplicity. The full extent,
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making has not yet been formally investigated.
Further and future developments
Currently, the ARMG and GRADE Working Group are
working on further development of the SoF tables in
two research projects. One research project, funded by
Cochrane Methods Innovation Fund, evaluates the de-
gree of acceptable flexibility beyond standard presenta-
tion of SoF tables. This evaluation includes investigating
which alternative columns are acceptable to decision
makers and should be included as alternatives in SoF
tables, for example, the addition of risk differences and
number needed to treat instead of the currently used
columns of assumed and corresponding risk. This eval-
uation will also include development of descriptions for
outcomes that could not be pooled, which columns can
be collapsed and which comparisons should be described
in the primary SoF tables. The second aim of the project
is to provide guidance on the standardization of com-
ments and footnotes for SoF tables, with a focus on the
explanations for downgrading and upgrading the quality
of a body of evidence. The third aim is to develop
guidance on what information to include in SoF tables
in diagnostic test accuracy reviews. The results of this
work, expected at the end of 2013, will be integrated in
updated training material to provide optimal guidance to
reviewer authors and users of reviews.
The DECIDE project, initiated and developed by the
GRADE working group, which runs from 2011 to 2015
(www.decide-collaboration.eu), attempts to take advan-
tage of technological advances to improve the SoF table.
As a result, the interactive SoF table (iSoF) uses electro-
nic presentation of information to reconcile precision
and simplicity through a layered approach to information
presentation. The top layer presents basic information,
while the deeper layers allow access to more details on de-
mand. In addition, the user has control over how many
and which outcomes the table displays and in which for-
mat (words, numbers, graphics) (see Figure 2).
The iSoF also has a column to express results in a
narrative format in addition to statistical formats, or in
lieu of these when statistical data are not available. The
multiple representation possibilities make the table
more flexible for presenting data from different kinds
of reviews.
Additional advantages of the iSoF include an inter-
active presentation and explanation of confidence inter-
vals and other statistical terms, and a responsive format
for printing and for displaying on different sizes and
types of electronic devices.
Future plans include the translation of the iSoF into
different languages. The iSoF will be incorporated in
GRADEpro and possibly other interfaces (for example,Cochrane Reviews, guideline products, electronic medical
records). The different versions would present the same
core information in potentially variable formats.
Plain language summary
The plain language summary (PLS, formerly called ‘syn-
opsis’) aims to summarize the results of a review in such
a way that consumers of health care without a medical
background can readily understand them. The current
format of the PLS was informed by a qualitative study
among consumers [6]. PLS has two parts: a title and a
body of test. In an effort to better disseminate Cochrane
evidence synthesis among consumers, efforts are under-
way to include a PLS in PubMed Health, a freely acces-
sible service by the US National Library of Medicine.
Ongoing improvement efforts are being directed towards
assuring consistency between the review and the PLS,
implementing short yet concise titles and reconsidering
the current word count limit of 400 words, while main-
taining understandability.
Example of a plain language summary [16]: com-
pression stockings for preventing deep vein thrombosis
(DVT) in airline passengers.
In the last few years, there has been increasing interest
in whether compression stockings (sometimes called ‘flight
socks’) reduce the risk of DVT (blood clots in the legs)
and other circulatory problems in airline passengers. The
stockings are worn throughout the flight and are similar to
those known to be effective in patients lying in bed after
an operation. By applying a gentle pressure, to the ankle in
particular, compression stockings help blood to flow.
Pressure combined with leg movement helps blood in
superficial veins to move to the deep veins and back to the
heart. The blood is then less likely to clot in the deep
veins, which could be fatal if the clot moves to the lungs.
Wearing compression stockings resulted in a very
large reduction in symptomless DVT among airline pas-
sengers who were allocated to wear compression stock-
ings compared to those allocated not to wear such
stockings. People who wore stockings also had much less
discomfort and swelling in their legs (edema) than those
who did not wear them.
These conclusions were based on nine trials, which
studied over 2,800 people, about half of whom were ran-
domly assigned to wearing stockings for a flight lasting
at least seven hours while the other half did not. None
of the passengers developed a DVT with symptoms
(slowly developing leg pain, swelling and increased tem-
perature) and no serious events (a blood clot in their
lungs (pulmonary embolus) or dying) were reported.
Passengers were carefully assessed after the flight to de-
tect any problems with the circulation of blood in their
legs, even if they had not noticed any problems them-
selves. There was a big difference in symptomless DVT
Figure 2 Snapshot of an interactive Summary of Findings (iSoF) table.
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risk from a few 10s per thousand passengers to 2 or 3
per thousand. Not all the trials reported on possible
problems with wearing stockings but in those that did,
the researchers said that the stockings were well toler-
ated, without any problems.
In connection with the SoF tables, research has been
conducted on how to communicate the results of syste-
matic reviews to consumers and how these are perceived
and understood [6,7,17]. This work is currently feeding
into the Plain Language Expectations for Authors of
Cochrane Summaries (PLEACS) project. The PLEACS
group has developed a set of minimum criteria for the
content of PLS (www.consumers.cochrane.org/PLEACS).
The purpose is to ensure that authors convey the key
question and findings of the review in a succinct and
clear manner to consumers. The group is also working
on improving the narrative reporting of results by testing
the inclusion of headings and numbers.
Current efforts include the development of a standar-
dized language to describe statistical results based on
effect size and quality of supporting evidence [6]. This
standardized language could be used in PLS and also in
abstracts of Cochrane Reviews. The iSoF project is pro-
totyping the use of PLS standardized sentences in their
own column in the table, providing the reader with a
narrative explanation of the gist of the results, next to
the numbers. The Collaboration is currently exploringhow standardized language could contribute to ensuring
the quality of translation of PLS and abstracts.
Future direction of PLS and SoF tables
A major future direction for the presentation formats of
PLS and SoF tables is making both of them usable by
both audiences and cross-linking them for those who
are interested in both. One could conceptualize PLS and
SoF tables, in particular, as the basic building blocks for
dissemination to end-users. Producing high quality PLS
and SoF tables and making them compatible and linked
would make it easy to produce dissemination products
targeting different audiences (for example, providers,
health policy makers [17], the press, guideline developers).
Furthermore, to avoid the risk of a one-size-fits-all ap-
proach to all recommendations, issues of who to apply
results to and attempting to divide them into different
risk groups (low, medium, high) deserves more work in
the future.
Training, support and tools
Among the core functions of the ARMG are training, pro-
viding specialist advice and contributing to software de-
velopment. Following the first GRADE Working Group
articles published in 2003 and 2004, the British Medical
Journal published a series of papers on the GRADE ap-
proach in 2004, authored by the GRADE Working Group.
Subsequently, in 2011, publication of a series of 20 papers
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series provides the basics of the GRADE approach, while
the second series offers detailed guidance on applying
GRADE and constructing SoF tables. Among the (local)
training activities are the GRADE/SoF workshops run by
the Dutch and German Cochrane centers and McMaster
University, and pre-conference and conference workshops
at Cochrane Colloquia and the meetings of the Guidelines
International Network. Examples of online training initia-
tives are the McMaster GRADE Online Learning Modules
(cebgrade.mcmaster.ca), YouTube videos and the slidecast
presentations of Cochrane Training. In February 2013, the
ARMG launched a question and answer webinar series.
To increase the capacity of training and support, the
ARMG is currently creating a network of members who
can be consulted for advice and support on making SoF
tables and GRADE profiles. Most of the support is cur-
rently provided by members of the ARMG at McMaster
University who have already helped many authors of
Cochrane Reviews. The new version of GRADEpro, which
will include training exercises and links to training mater-
ial, will be part of the Guideline Development Tool (www.
guidelinedevelopment.org), a comprehensive new tool for
developing evidence-based guidance. An update of the
currently available two chapters of the ARMG in the
Cochrane Handbook for Systematic Reviews on Interven-
tions is expected in 2013 [3,18].
Current debates and challenges
Current issues of debate and controversy include opti-
mal presentation formats of SoF tables, the training and
perceived additional effort involved in using GRADE,
and the extent to which authors of Cochrane Reviews
should provide explicit guidance to target audiences of
patients, clinicians and policy-makers. The first of these
should be settled by ongoing empirical investigation and
the interactive SoF table. The other two issues may be
more challenging to solve. Criticisms of GRADE include
its complexity, the time involved in its application, and
the extent to which its application yields ratings of low
confidence in effect estimates. GRADE proponents argue
that the complexity is not in GRADE but in the issues that
GRADE has brought to light (for example, complex judg-
ments related to precision, directness and consistency,
and thresholds for when to rate down confidence regar-
ding these components and for risk of bias). If one is
going to address, rather than ignore, these issues, GRADE
provides a structure that simplifies, rather than increasing
the complexity. GRADE proponents also argue that the
time required is in preparing summaries that allow one to
address the issues of evidence evaluation, rather than in
the evaluation itself. GRADE may indeed lower the work-
load by providing a structure to what has often been an
unstructured and, therefore, more disorganized andlaborious effort. With respect to the issue of the likelihood
that application of GRADE will result in conclusions of
low confidence in effect estimates, paucity of high quality
evidence is not the fault of GRADE or the SoF table.
More importantly, GRADE and ARMG are attentive and
respectful to these concerns. Where this attentiveness plays
out vividly at the moment is in the cautious approach to
dealing with uncertainty related to baseline risk or diagnos-
tic test accuracy studies. Greater attention to this up to
now relatively neglected area will increase complexity, may
increase time required, and will increase the likelihood of
ratings of low confidence in effect estimates. GRADE is
currently working on advancing our conceptual under-
standing of these issues and providing a way to advance
their consideration while minimizing associated burdens
on systematic review authors and guideline developers.
The Cochrane Collaboration is explicit that systematic
review authors should not make recommendations. At
the same time, audiences seek guidance on how results
should be applied, and Cochrane provides the oppor-
tunity for authors to reflect on the implications of their
review for clinical practice and public policy. These com-
peting considerations create tension. A potential solution
in the clinical, and perhaps the health policy area, is for
authors to highlight particular constellations of values and
preferences and their implications, given the results, for
particular courses of action.
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